title: Effect of administration time of exenatide on satiety responses, blood glucose, and adverse events in healthy volunteers.
abstract: The objective was to investigate whether varying administration time of exenatide affects the magnitude of satiety responses, blood glucose, and adverse events in healthy volunteers. In this randomized, single-blind, placebo-controlled, 4-period crossover, single-dose study, the authors measured satiety responses, blood glucose, and adverse events in 20 participants receiving exenatide (10 µg) at either -60 minutes, -30 minutes, or -15 minutes or placebo at -30 minutes relative to a standardized test meal. Compared with placebo, exenatide reduced caloric intake (P = .0059), food intake (P = .0032), and glucose concentrations at 60 (P < .001) and 120 minutes after meals (P = .015). Nausea (63% vs 20%), reduced appetite (43% vs 10%), and vomiting (18% vs 0%) occurred more frequently in exenatide-treated subjects compared with placebo (P < .05). Significant differences were noted in caloric intake (P = .0149) and food intake (P = .0205) based on the administration time of exenatide, with doses given further from meals producing reduced feeding responses. No such difference was found in postprandial glucose concentrations or adverse events based on timing of exenatide administration. Single-dose exenatide administered further from mealtime had an increased magnitude on satiety responses in healthy volunteers. Postprandial glucose concentrations and the frequency of adverse events did not differ by the administration time of exenatide.
authors.affiliation: Department of Pharmacy Practice, Eugene Applebaum College of Pharmacy & Health Sciences, Wayne State University, 259 Mack Ave, Detroit, MI 48201-2417, USA. nickipinelli@wayne.edu
authors.forename: Nicole R
authors.initials: NR
authors.lastname: Pinelli
authors.forename: Arin
authors.initials: A
authors.lastname: Jantz
authors.forename: Zachary
authors.initials: Z
authors.lastname: Smith
authors.forename: Amenah
authors.initials: A
authors.lastname: Abouhassan
authors.forename: Christina
authors.initials: C
authors.lastname: Ayar
authors.forename: Nadim A
authors.initials: NA
authors.lastname: Jaber
authors.forename: Anthony W
authors.initials: AW
authors.lastname: Clarke
authors.forename: Randall L
authors.initials: RL
authors.lastname: Commissaris
authors.forename: Linda A
authors.initials: LA
authors.lastname: Jaber
mesh_terms: D000328:Adult; D001786:Blood Glucose / Q000187:drug effects*; D018592:Cross-Over Studies; D004334:Drug Administration Schedule; D004435:Eating / Q000187:drug effects; D000077270:Exenatide; D005260:Female; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology*; D008297:Male; D010455:Peptides / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology*; D019518:Postprandial Period; D012528:Satiety Response / Q000187:drug effects*; D016037:Single-Blind Method; D013997:Time Factors; D014688:Venoms / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology*; D055815:Young Adult
chemical_list: D001786:Blood Glucose; D007004:Hypoglycemic Agents; D010455:Peptides; D014688:Venoms; D000077270:Exenatide